Your browser doesn't support javascript.
loading
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial.
Qiao, Qian; Han, Chun; Ye, Sisi; Li, Juan; Shao, Guoliang; Bai, Yuxian; Xu, Aibing; Sun, Meili; Wang, Wei; Wu, Jian; Huang, Ming; Song, Lijie; Huang, Luke; Liu, Ting; Liu, Wei; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle; Bai, Li.
Affiliation
  • Qiao Q; Chinese People's Liberation Army (PLA) Medical School, Beijing, China.
  • Han C; Daytime Chemotherapy Center, Beijing Arion Cancer Center, Beijing, China.
  • Ye S; Department of Medical Oncology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
  • Li J; Department of Medical Oncology, Chinese People's Liberation Army (PLA) General Hospital, Beijing, China.
  • Shao G; Intervention Department, Zhejiang Cancer Hospital, Hangzhou, China.
  • Bai Y; Department of Gastrointestinal Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
  • Xu A; Department of Medical Oncology, Nantong Tumor Hospital, Nantong, China.
  • Sun M; Department of Medical Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Wang W; Department of Gastroenterology and Urology II, Hunan Cancer Hospital, Changsha, China.
  • Wu J; Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Huang M; Intervention Department, Yunnan Cancer Hospital&The Third Affiliated Hospital of Kunming Medical University&Yunnan Cancer Center, Kunming, China.
  • Song L; Department of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Huang L; Akeso Biopharma, Inc., Zhongshan, China.
  • Liu T; Akeso Biopharma, Inc., Zhongshan, China.
  • Liu W; Akeso Biopharma, Inc., Zhongshan, China.
  • Wang ZM; Akeso Biopharma, Inc., Zhongshan, China.
  • Li B; Akeso Biopharma, Inc., Zhongshan, China.
  • Xia M; Akeso Biopharma, Inc., Zhongshan, China.
  • Bai L; Chinese People's Liberation Army (PLA) Medical School, Beijing, China.
Front Immunol ; 14: 1238667, 2023.
Article in En | MEDLINE | ID: mdl-37942328
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Limits: Humans Language: En Journal: Front Immunol Year: 2023 Type: Article Affiliation country: China
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Limits: Humans Language: En Journal: Front Immunol Year: 2023 Type: Article Affiliation country: China